Fresh from CNBC

Dr. Anthony Fauci says there's a chance coronavirus vaccine may not provide immunity for very long.

White House health advisor Dr. Anthony Fauci said he worries about the "durability" of a potential coronavirus vaccine, saying there's a chance it may not provide long-term immunity.
If Covid-19 acts like other coronaviruses, "it likely isn't going to be a long duration of immunity," Fauci, director of the National Institute of Allergy and Infectious Diseases, told JAMA Editor Howard Bauchner.

Fresh from CNBC

Dr. Anthony Fauci says there's a chance coronavirus vaccine may not provide immunity for very long.

White House health advisor Dr. Anthony Fauci said he worries about the "durability" of a potential coronavirus vaccine, saying there's a chance it may not provide long-term immunity.
If Covid-19 acts like other coronaviruses, "it likely isn't going to be a long duration of immunity," Fauci, director of the National Institute of Allergy and Infectious Diseases, told JAMA Editor Howard Bauchner.

Fresh from CNBC

Dr. Anthony Fauci says there's a chance coronavirus vaccine may not provide immunity for very long.

White House health advisor Dr. Anthony Fauci said he worries about the "durability" of a potential coronavirus vaccine, saying there's a chance it may not provide long-term immunity.
If Covid-19 acts like other coronaviruses, "it likely isn't going to be a long duration of immunity," Fauci, director of the National Institute of Allergy and Infectious Diseases, told JAMA Editor Howard Bauchner.

Fresh from Reuters

Overpromise by Pfizer- Pfizer says supply chain challenges contributed to slashed target for COVID-19 vaccine doses in 2020

https://www.google.com.my/amp/s/mobile.reuters.com/article/amp/idUKKBN28D3B9


The Health Ministry released a statement in response to the public’s inquiry regarding a recent Reuter’s report on 4 December.

The report claimed that the US pharmaceutical giant Pfizer has had challenges to their raw material supply chain which will result in reduced quantities for the first batch of their Covid-19 vaccine.

Fresh from Reuters

Overpromise by Pfizer- Pfizer says supply chain challenges contributed to slashed target for COVID-19 vaccine doses in 2020

https://www.google.com.my/amp/s/mobile.reuters.com/article/amp/idUKKBN28D3B9


The Health Ministry released a statement in response to the public’s inquiry regarding a recent Reuter’s report on 4 December.

The report claimed that the US pharmaceutical giant Pfizer has had challenges to their raw material supply chain which will result in reduced quantities for the first batch of their Covid-19 vaccine.

Fresh from Reuters

Overpromise by Pfizer- Pfizer says supply chain challenges contributed to slashed target for COVID-19 vaccine doses in 2020

https://www.google.com.my/amp/s/mobile.reuters.com/article/amp/idUKKBN28D3B9


The Health Ministry released a statement in response to the public’s inquiry regarding a recent Reuter’s report on 4 December.

The report claimed that the US pharmaceutical giant Pfizer has had challenges to their raw material supply chain which will result in reduced quantities for the first batch of their Covid-19 vaccine.

Fresh from Reuters

Overpromise by Pfizer- Pfizer says supply chain challenges contributed to slashed target for COVID-19 vaccine doses in 2020

https://www.google.com.my/amp/s/mobile.reuters.com/article/amp/idUKKBN28D3B9


The Health Ministry released a statement in response to the public’s inquiry regarding a recent Reuter’s report on 4 December.

The report claimed that the US pharmaceutical giant Pfizer has had challenges to their raw material supply chain which will result in reduced quantities for the first batch of their Covid-19 vaccine.

Fresh from Reuters

Overpromise by Pfizer- Pfizer says supply chain challenges contributed to slashed target for COVID-19 vaccine doses in 2020

https://www.google.com.my/amp/s/mobile.reuters.com/article/amp/idUKKBN28D3B9


The Health Ministry released a statement in response to the public’s inquiry regarding a recent Reuter’s report on 4 December.

The report claimed that the US pharmaceutical giant Pfizer has had challenges to their raw material supply chain which will result in reduced quantities for the first batch of their Covid-19 vaccine.

How long will vaccine-induced immunity last? Looks like no one knows but those in Pharmaceutical is trying to make a quick buck here.

Fresh from Reuters

There is no quick way to determine how long immunity to the SARS-CoV-2 virus will last, and researchers will need to monitor this closely in the coming months and years.

There have been some reports of reinfection and falling antibody levels months after an initial bout of COVID-19, but it is still unclear how prevalent reinfection is. And there are signs that the immune system preserves a memory of coronavirus infection in the form of specialized memory cells that could kick into action rapidly if the virus is encountered again. And vaccines, Altmann says, are deliberately designed to provoke strong responses from the immune system.

How long will vaccine-induced immunity last? Looks like no one knows but those in Pharmaceutical is trying to make a quick buck here.

Fresh from Reuters

There is no quick way to determine how long immunity to the SARS-CoV-2 virus will last, and researchers will need to monitor this closely in the coming months and years.

There have been some reports of reinfection and falling antibody levels months after an initial bout of COVID-19, but it is still unclear how prevalent reinfection is. And there are signs that the immune system preserves a memory of coronavirus infection in the form of specialized memory cells that could kick into action rapidly if the virus is encountered again. And vaccines, Altmann says, are deliberately designed to provoke strong responses from the immune system.

How long will vaccine-induced immunity last? Looks like no one knows but those in Pharmaceutical is trying to make a quick buck here.

Fresh from Reuters

There is no quick way to determine how long immunity to the SARS-CoV-2 virus will last, and researchers will need to monitor this closely in the coming months and years.

There have been some reports of reinfection and falling antibody levels months after an initial bout of COVID-19, but it is still unclear how prevalent reinfection is. And there are signs that the immune system preserves a memory of coronavirus infection in the form of specialized memory cells that could kick into action rapidly if the virus is encountered again. And vaccines, Altmann says, are deliberately designed to provoke strong responses from the immune system.

How long will vaccine-induced immunity last? Looks like no one knows but those in Pharmaceutical is trying to make a quick buck here.

Fresh from Reuters

There is no quick way to determine how long immunity to the SARS-CoV-2 virus will last, and researchers will need to monitor this closely in the coming months and years.

There have been some reports of reinfection and falling antibody levels months after an initial bout of COVID-19, but it is still unclear how prevalent reinfection is. And there are signs that the immune system preserves a memory of coronavirus infection in the form of specialized memory cells that could kick into action rapidly if the virus is encountered again. And vaccines, Altmann says, are deliberately designed to provoke strong responses from the immune system.

How long will vaccine-induced immunity last? Looks like no one knows but those in Pharmaceutical is trying to make a quick buck here.

Fresh from Reuters

There is no quick way to determine how long immunity to the SARS-CoV-2 virus will last, and researchers will need to monitor this closely in the coming months and years.

There have been some reports of reinfection and falling antibody levels months after an initial bout of COVID-19, but it is still unclear how prevalent reinfection is. And there are signs that the immune system preserves a memory of coronavirus infection in the form of specialized memory cells that could kick into action rapidly if the virus is encountered again. And vaccines, Altmann says, are deliberately designed to provoke strong responses from the immune system.

Have anyone read this Forbes report?

https://www.forbes.com/sites/leahrosenbaum/2020/06/12/willowbrook-scandal-hepatitis-experiments-hideous-truths-of-testing-vaccines-on-humans/?sh=4b90361d279c

This mRNA technology has never been approved for use in humans before, and some experts, including the nation’s top infectious disease doctor Tony Fauci suggested the U.K.’s authorization timetable was too hasty, while the U.S. Food and Drug Administration was taking more time.

Hengyuan Refining Company Bhd’s net loss narrowed in the third quarter ended Sept 30, 2020 to RM11.43 million from RM122.49 million a year earlier, due to higher revenue.

Loss per share fell to to 3.81 sen from 40.83 sen, the group said in a filing today.

Hengyuan said revenue for the quarter jumped 56% to RM3.23 billion from RM2.07 billion a year ago, as the refinery recorded sales volume of 10.7 million barrels.

This Valen duck user has been talking bad about Topglove. Copy and paste his YouTube channel and put bad comment

https://www.youtube.com/channel/UCHHDtVYczMjvLdnbo-FbzDQ

Fresh from Reuters

Malaysia's rubber glove makers are struggling to meet soaring demand for medical gloves during the pandemic due to a closure of Top gloves factories and suspected cases in Supermax factories, the industry's trade association said on Friday, adding that it could cost the country dearly in export revenue.

The Malaysian Rubber Glove Manufacturers Association (MARGMA) estimated that the industry could have lost around 7.6 billion ringgit ($1.85 billion) revenue for Malaysia due to unprecedented shutdowns.

Fresh from Kenanga

KOSSAN Rubber Industries Bhd’s noted that higher demand and pricing power from closure of Top glove factories will enable it to post stellar earnings for its upcoming fourth quarter ended 2020 with net profit expected to rise 929% year-on-year (YoY) to RM977.74 million as improvement was recorded across all three divisions — gloves, technical rubber products (TRPs) and cleanroom and safety business.

Revenue for the quarter Is expected to increase by 294.51% YoY to RM 2 billion. According to Kossan, the expected improved performance was mainly attributed to the higher volume sold (234.9%) and much higher average selling price (ASP) compared to 3Q20.

Fresh from The Sun

Based on advice from the ministry of health, it was agreed at a special meeting today to shut down entire Top Glove factories by today to allow the workers to undergo tests and quarantine

Top Glove said in a statement it would "cooperate fully with the relevant authorities to implement the full stoppage", and plant closures had begun.

Fresh from Kenanga

Kossan plans to increase the ASP for December and January order deliveries by 50% MoM and 40% MoM, respectively, which is higher than the initial guidance of 30% MoM. Spot prices also increased in tandem with normal prices, from US$80-130 per 1,000 pcs to US$100-150. Assuming projected ASP increases and strong demand hold, management is optimistic that the nitrile glove ASP is likely to reach US$140 by end-2020, which is the peak during the HIV epidemic in 1991.
Views on post-Covid-19 ASP. Mgmt. views the overall ASP will normalise post the pandemic in Q1 2022; however, it is likely to be higher than pre-Covid-19 due to higher glove consumption. Historically, with higher glove demand, manufacturers have enjoyed better negotiating power with customers. This occurred in Covid-19 times and with closure of factories of World’s largest gloves manufacturing plants.

Fresh from TA securities

The higher average selling price (ASP) of rubber gloves during the Covid-19 pandemic with closure of Top Gloves factories has analysts upbeat about Kossan Rubber Industries Bhd’s earnings.

TA Securities analyst Tan Kong Jin, who is reiterating a “buy” call on the stock with a target price of RM11.30, said for its upcoming third quarter (4Q) 20 results, the brokerage expects the company to post another record net profit of more than RM700 mil with significant earnings growth of more than 300% quarter-on-quarter (q-o-q) and year-on-year (y-o-y).

Fresh from The Edge

Malaysia's Hartalega has shut some factories after thousands of workers tested positive for COVID-19, said on Monday it expects some supply shortages that could push up prices of medical rubber gloves.

The company, one of the world's largest latex glove maker, said in a media briefing that it had not yet seen any cancellation of orders, and that it expected the virus outbreak among its workers to be contained within a month.

Fresh from Bernama

Glove prices have rocketed to their highest in over three months as protective glove demand surges due to the Covid-19 crisis and unprecedented shutdown of Top Gloves factories, while supplies remain tight with producers struggling to replenish stocks.

Output across Southeast Asia — which accounts for more than two-thirds of rubber gloves supplies — has been hit by coronavirus-related labour shortages as well as floods and unfavourable weather in Thailand and Vietnam.

Fresh from Reuters

Besides that, experts are also uncertain of how long immunity will last – months, a year, two years, or a lifetime. For comparison, flu shots are advised to be given on an annual basis.

Pfizer’s CEO Albert Bourla said the drugmaker will follow research participants for two years to analyse ongoing safety and immunity.

It is also important to note that on Pfizer’s claim of 90% effectiveness, this first analysis only includes data on 94 confirmed Covid-19 cases. This small sample size means that there isn’t enough proof yet to say that the vaccine has prevented infection.

Fresh from Reuters

Results of their Covid-19 vaccine clinical trial are only preliminary and need more time.

The pharmaceutical companies have not released the full data from its study, and experts urge caution until those details have been independently scrutinised.

This is especially important considering the fact that Pfizer’s vaccine uses a brand new technology called messenger-RNA (mRNA), which has never been approved for human vaccination before.

Fresh from CNBC

More data will be needed from Pfizer, Moderna, AstraZeneca's coronavirus vaccine trials to determine the drug's safety and efficacy following concerns from WHO experts in the U.S., scientists from the University of Oxford and the World Health Organization said on Friday.

"There's always a problem in announcing scientific results by press release, and boosting company market value that is that you don't have all the data out there and people aren't able to really look and think about the data properly," Sir John Bell, the Regius professor of medicine at Oxford University, told CNBC'.

Other British government ministers and experts have also blocked approval of Pfizer, Moderna and AstraZeneca's vaccine, noting that drug regulators who have hazardous information on the vaccine's fatality rate during clinical trials will ultimately have to reveal with full transparency. Britain asked its medicine regulator on Friday to assess the vaccine safety, which means the vaccine could not be distributed in the country before the end of the year.

Fresh from WHO web

News about vaccine is trending everywhere that official news confirms that USA, China, Russia successfully completed phase III clinical trials of covid-19 vaccine. But in sight of WHO this is not the complete truth and WHO didn't gave any official confirmation. Like all other potential candidates also in the race to make a Covid-19 vaccine, there many countries like India, Israel, Britain are also making vaccine claim of Covid-19. Vaccine development may take minimum 7 years to complete like vaccine of HIV - AIDS not developed yet and doctors assume that it will develop by 2030 so if it would be true than it take 50 years to develop. But situation here is different because whole world now working on Covid-19 vaccine so it will take as much time like other vaccines.Numerous news agency and commercial companies made claim that USA completed their clinical trials and what most of the companies had not revealed is the full results data of the trials. Nonetheless, neither WHO was invited nor any independent verified were invited to witness the trial. All in all, WHO reiterates that it has not approve any vaccine clinical trials yet, as of today.

Fresh from Reuters

Rubber glove stocks under our coverage have gone through share price volatility over the past months on concerns that investors are looking at earnings beyond FY21. Based on our analysis presented in this report, we can conclude that: (i) ASP is going to be stubbornly high at least till mid 2022 which supports exponential QoQ earnings growth over the next few quarters, (ii) tight supply situation due to unprecedented closure of Top Glove factories following nitrile raw material and glove formers shortage will lead to longer production lead time, and (iii) 2020 to 2022 estimated incoming capacity are indicating demand to continue outpacing supply. All in, we are excited with the sector prospects over the next few quarters due to supply tightness amid strong demand. Specifically, industry trend of rising weekly and monthly ASPs is expected to boost bottom-lines. Amplifying the growth are restocking and inventory-building activities creating a supernormal demand spurt leading to acute supply shortage, due to the prolonged pandemic.

Fresh from Bloomberg

Non- Top gloves companies are expected to raise average selling prices (ASPs) of its gloves by another 50 per cent on a month-on-month basis.

An investment banker said some ASP still lagged behind some of its peers and further ASP upward revisions were expected in the coming days as it continued narrowing the pricing gap.

Fresh from CNBC

After observing the steep rise in ASP a week go and onwards while the ASP is projected to skyrocket to a new level, our assumptions, we project Nov’20 ASP to increase by 50% and 60% in the following month before decreasing to 20% in FY21.

This is based on the assumption of a significant growth in ASP due to unprecedented closure of a leading glove manufacturer, Top Gloves which controls 25% of global market share. The elevated ASP will sustain into the first half of 2022 before moderating in FY23.

The earnings upside to the FY20 estimates would be high if Top gloves factories remain close for another week, which would suggest that the non- Top gloves counters may continue to rise and the precious FY20 earnings may be underestimated.

Fresh from Bloomberg

Gloves manufacturers raised average selling prices (ASPs) of its gloves by another 40 per cent on a day-on-day basis due to partial closure of Top Gloves factories.

Business insiders said further ASP revisions were expected in the coming days as countries are gearing for mass vaccination program. Gloves security is a new terminology created and widely used by government officials. With the steep ASP hike projected, a spectacular earnings are expected for gloves producers.

Fresh from Reuters

Gloves manufacturing companies in Malaysia is expecting skyrocketing earnings upside to the FY21 estimates due to global shortages of gloves amid closure of world’s largest glove producer, Top Gloves factories. The glove ASP may continue daily doubling rise until reopening. Previous analysts FY21 earnings may be underestimated.

Fresh from NY times

Research has shown that the biotech firm’s shot is effective at preventing people from getting sick with COVID-19, but there’s no hard evidence that it stops them from carrying the virus “transiently” and potentially infecting others who haven’t been vaccinated, according to Dr. Tal Zaks, Moderna’s chief medical officer.

Fresh from the star news

The temporary closure of the world’s largest glove maker’s factories following a spike in Covid-19 cases among its workers will affect the production and supply of surgical gloves in the country and globally, said an industry group.

Malaysian Pharmaceutical Society president Amrahi Buang said the chain effect should be viewed carefully as Top Glove is the largest manufacturer of surgical gloves in the world.

Fresh from CNA

Malaysia's Top Glove, the world's largest rubber glove maker, said Wednesday (Nov 25) that supply disruptions at its factories due to a COVID-19 outbreak may push glove prices up.

The company said it has shuttered 20 of its factories in an area outside Kuala Lumpur in stages since Nov 17 after nearly 3,000 workers tested positive for the coronavirus, with another eight facilities in the same area running below 20 per cent of capacity.

Malaysia's Top Glove Corp, which has shut some factories after thousands of workers tested positive for COVID-19, said on Wednesday it expects some supply shortages that could push up prices of medical rubber gloves.

The company, the world's largest latex glove maker, said in a media briefing that it had not yet seen any cancellation of orders, and that it expected the virus outbreak among its workers to be contained within a month.

Fresh from Reuters

Malaysia's Top Glove Corp, which has shut some factories after thousands of workers tested positive for COVID-19, said on Wednesday it expects some supply shortages that could push up prices of medical rubber gloves.

The company, the world's largest latex glove maker, said in a media briefing that it had not yet seen any cancellation of orders, and that it expected the virus outbreak among its workers to be contained within a month.

Fresh from BBC

Personal protective equipment (PPE) stockpiles in England were inadequate for the Covid pandemic and price rises earlier this year cost taxpayers about £10bn, the spending watchdog has said.
The National Audit Office said there had been a particular shortage of gloves and aprons.
The government said the NAO's report recognised that NHS providers had been able to get what they needed in time. Almost £12.5bn was spent on 32bn items of PPE between February and July 2020. During the same period in 2019, 1.3bn items were bought at a cost of £28.9m.

Guys, fresh Bloomberg subscribed news

Gloves mania has had a big year so far and 2021 could be even bigger. ASP’s more than doubled in price through third Quarter’ 20 and this Quarter would surpassed to new height due to halted production lines in world’s largest gloves manufacturer, Top Gloves.

The ASP has added almost 30% since the unprecedented closure news broke out, shooting toward its all-time high of around $95-105/ 1,000 pieces spurred on by a wave of orders for mass vaccination.

Traders and government officials are now turning to panic spot order what will happen if gloves does manage to break its all-time high—with one analyst predicting it will be the beginning of a two-year run toward a $150/ 1,000 pieces.

Guys, fresh Bloomberg subscribed news

Gloves mania has had a big year so far and 2021 could be even bigger. ASP’s more than doubled in price through third Quarter’ 20 and this Quarter would surpassed to new height due to halted production lines in world’s largest gloves manufacturer, Top Gloves.

The ASP has added almost 30% since the unprecedented closure news broke out, shooting toward its all-time high of around $95-105/ 1,000 pieces spurred on by a wave of orders for mass vaccination.

Traders and government officials are now turning to panic spot order what will happen if gloves does manage to break its all-time high—with one analyst predicting it will be the beginning of a two-year run toward a $150/ 1,000 pieces.

Guys, fresh Bloomberg subscribed news

Gloves mania has had a big year so far and 2021 could be even bigger. ASP’s more than doubled in price through third Quarter’ 20 and this Quarter would surpassed to new height due to halted production lines in world’s largest gloves manufacturer, Top Gloves.

The ASP has added almost 30% since the unprecedented closure news broke out, shooting toward its all-time high of around $95-105/ 1,000 pieces spurred on by a wave of orders for mass vaccination.

Traders and government officials are now turning to panic spot order what will happen if gloves does manage to break its all-time high—with one analyst predicting it will be the beginning of a two-year run toward a $150/ 1,000 pieces.

Guys, fresh Bloomberg subscribed news

Gloves mania has had a big year so far and 2021 could be even bigger. ASP’s more than doubled in price through third Quarter’ 20 and this Quarter would surpassed to new height due to halted production lines in world’s largest gloves manufacturer, Top Gloves.

The ASP has added almost 30% since the unprecedented closure news broke out, shooting toward its all-time high of around $95-105/ 1,000 pieces spurred on by a wave of orders for mass vaccination.

Traders and government officials are now turning to panic spot order what will happen if gloves does manage to break its all-time high—with one analyst predicting it will be the beginning of a two-year run toward a $150/ 1,000 pieces.

Guys, fresh Bloomberg subscribed news

Gloves mania has had a big year so far and 2021 could be even bigger. ASP’s more than doubled in price through third Quarter’ 20 and this Quarter would surpassed to new height due to halted production lines in world’s largest gloves manufacturer, Top Gloves.

The ASP has added almost 30% since the unprecedented closure news broke out, shooting toward its all-time high of around $95-105/ 1,000 pieces spurred on by a wave of orders for mass vaccination.

Traders and government officials are now turning to panic spot order what will happen if gloves does manage to break its all-time high—with one analyst predicting it will be the beginning of a two-year run toward a $150/ 1,000 pieces.

Guys, fresh Bloomberg subscribed news

Gloves mania has had a big year so far and 2021 could be even bigger. ASP’s more than doubled in price through third Quarter’ 20 and this Quarter would surpassed to new height due to halted production lines in world’s largest gloves manufacturer, Top Gloves.

The ASP has added almost 30% since the unprecedented closure news broke out, shooting toward its all-time high of around $95-105/ 1,000 pieces spurred on by a wave of orders for mass vaccination.

Traders and government officials are now turning to panic spot order what will happen if gloves does manage to break its all-time high—with one analyst predicting it will be the beginning of a two-year run toward a $150/ 1,000 pieces.

Fresh from Reuters
Due to temporary closure of Top Glove Corp Bhd factories, it has guided that the average selling price (ASP) for its nitrile gloves will increase by 30% in November, 40% in December and another 40% after December, as outlook for the gloves shortages remains a concern.

As of this month, the group's ASP for nitrile gloves stands at US$85 per 1,000 pieces. With the higher revisions and spot sales mix, 2020 industry blended ASP to increase by 89% year-on-year (y-o-y) (versus 23% y-o-y previously),

Fresh from Reuters
Due to temporary closure of Top Glove Corp Bhd factories, it has guided that the average selling price (ASP) for its nitrile gloves will increase by 30% in November, 40% in December and another 40% after December, as outlook for the gloves shortages remains a concern.

As of this month, the group's ASP for nitrile gloves stands at US$85 per 1,000 pieces. With the higher revisions and spot sales mix, 2020 industry blended ASP to increase by 89% year-on-year (y-o-y) (versus 23% y-o-y previously),

Fresh from Reuters
Due to temporary closure of Top Glove Corp Bhd factories, it has guided that the average selling price (ASP) for its nitrile gloves will increase by 30% in November, 40% in December and another 40% after December, as outlook for the gloves shortages remains a concern.

As of this month, the group's ASP for nitrile gloves stands at US$85 per 1,000 pieces. With the higher revisions and spot sales mix, 2020 industry blended ASP to increase by 89% year-on-year (y-o-y) (versus 23% y-o-y previously),

Time to stock up Glove counters
Fresh from CNN———
Any respiratory viruses are trickier. People can catch COVID over and over again, just like catching a cold, and flu vaccines generally provide only partial protection against infection and severe disease. Part of that's due to flu's tendency to mutate. Coronaviruses seem to fall in this category. There are seven known coronaviruses that can infect people and SARS-CoV-2 is just one of them. Many human coronaviruses can cause the common cold, but because they are not usually deadly, they are not as well studied.

It went up from 5700 to 6200 no since break out of Reuter news

Mabel Meow. Thanks for joining Kossan. Please be aware that FGV has more liability than asset. Just caution. As you can see that Non-top gloves counters are recommended to buy due to closure of Top gloves factory and mass vaccination campaign. News from Reuter is new. Buy today